Free shipping on all orders over $ 500


Cat. No. M15101
Cemiplimab Structure

Libtayo; REGN-2810; cemiplimab-rwlc

Size Price Availability
1mg USD 430  USD430 4-7 Days
5mg USD 1290  USD1290 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99% , Endotoxin < 2 EU/mg
  • COA
  • MSDS
Biological Activity

Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Source: HEK293

In vivo: Cemiplimab (REGN2810) binds to the humanized PD-1 receptor and inhibits tumor growth in MC38 mice in human PD-1 knockout mice. REGN2810 has a high affinity for cynomolgus monkey PD-1, and its pharmacokinetics and toxicology were studied in cynomolgus monkey. High dose REGN2810 was well tolerated without adverse immune-related effects. In vitro: In cell-based assays, REGN2810 reversed PD-1-dependent attenuation of T-cell receptor signaling and enhanced human primary T-cell responses.

Chemical Information
CAS Number 1801342-60-8
Solubility (25°C) N/A
Storage 4°C , protect from light , dry , sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Krishnansu S Tewari, et al. N Engl J Med. Survival with Cemiplimab in Recurrent Cervical Cancer

[2] Alexander J Stratigos, et al. Lancet Oncol. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

[3] Ahmet Sezer, et al. Lancet. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

[4] Arnold Lee, et al. Drugs. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma

[5] Michael R Migden, et al. N Engl J Med. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Related PD-1/PD-L1 Products
Human PD-L1 inhibitor V

Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.


ARB-272572 is a potent small molecule PD-L1 inhibitor with an IC50 value of 400 pM.


AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.


CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1.


Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties.

Abmole Inhibitor Catalog

Keywords: Cemiplimab, Libtayo; REGN-2810; cemiplimab-rwlc supplier, PD-1/PD-L1, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.